Integra LifeSciences Q2 revenue steady as SurgiMend relaunch nears
Integra LifeSciences Holdings reported second-quarter 2026 revenues of $418.8 million, a 0.8% increase on a reported basis and 0.7% on an organic basis year over year. The Princeton, New Jersey-listed medical technology company returned to GAAP profitability, posting net income of $4.5 million against a net loss of $484.1 million in the comparable period of 2025, a quarter heavily distorted by a $511.4 million goodwill impairment charge.
Adjusted earnings per diluted share rose to $0.56 from $0.45 in Q2 2025, while adjusted EBITDA improved to $78.4 million, representing an 18.7% margin compared with 17.1% a year earlier. Adjusted gross margin expanded modestly to 61.3% from 60.7%, reflecting reduced Braintree transition costs and broader operational discipline. Net debt stood at $1.6 billion at the quarter end, with a leverage ratio of 4.1x and total liquidity of approximately $496 million.
Segment performance
Integra's Specialty Surgery division, which accounts for roughly 70% of group revenues, grew 1.7% on a reported basis to $309.3 million. Neurosurgery was the primary driver, with the Certas Plus programmable valve, Bactiseal antimicrobial catheter, and the CUSA ultrasonic aspiration system each contributing to 1.9% organic growth in the Neuro sub-category. Instruments grew 3.2% organically, though ENT declined 1.9% as gains in MicroFrance products were offset by weakness elsewhere in the portfolio.
The Tissue Reconstruction segment, representing around 30% of revenues, contracted 1.9% to $109.5 million. Wound reconstruction declined at a mid-single-digit rate, with growth in DuraSorb and the relaunch of PriMatrix unable to offset falls in MicroMatrix and Integra Skin. The company noted that Integra Skin faced a tough prior-year comparison linked to back-order clearances in Q2 2025. Private-label sales within the segment grew 4.7%.
SurgiMend relaunch and operational outlook
The most significant operational milestone flagged in the results was the start of production at Integra's Braintree, Massachusetts manufacturing facility. The site is intended to underpin the planned fourth-quarter relaunch of SurgiMend, a collagen-based soft-tissue reconstruction matrix used primarily in hernia and breast reconstruction procedures. SurgiMend's removal from the market following quality and supply disruptions had been a material drag on the Tissue Reconstruction segment, and its return is viewed by management as a key step in restoring segment momentum.
Chairman and chief executive Stuart Essig said the quarter reflected "meaningful progress" on supply reliability and quality, and highlighted a more aligned commercial organisation and continued balance sheet deleveraging as supporting factors.
For full-year 2026, Integra trimmed its reported revenue guidance to a range of $1.654 billion to $1.695 billion, citing the impact of a stronger US dollar, while reaffirming organic growth guidance of 0.8% to 3.3% and adjusted EPS guidance of $2.40 to $2.50. Third-quarter reported revenue is guided in the range of $410 million to $425 million, implying organic growth of 1.9% to 5.7%.
The broader medical devices sector is navigating a mixed environment: elective procedure volumes have largely normalised post-pandemic, but device manufacturers face margin pressure from tariffs, elevated interest rates, and currency headwinds. Integra's leverage ratio of 4.1x is higher than many mid-cap peers, and investors will watch whether the SurgiMend relaunch translates into meaningful Tissue Reconstruction recovery in the second half. A successful return of the product would remove one of the more visible overhangs on the company's near-term growth story.